Crescent moves to close the bispecific gap
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
ADC slides on latest Zynlonta update
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
Genmab pushes rina-S into its third phase 3
The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.
Blenrep against the odds
The FDA has cleared GSK’s drug again, after a no from the advisory committee.
Triple meeting 2025 – Zai discloses pivotal DLL3 plans
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
